首页> 外文期刊>Breast Cancer Research and Treatment >Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells
【24h】

Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells

机译:与同种异体乳腺癌细胞系融合的树突状细胞诱导针对自体乳腺癌细胞的肿瘤抗原特异性CTL反应

获取原文
获取原文并翻译 | 示例
           

摘要

Dendritic cell (DC)/tumor cell fusion vaccine has been revealed as a promising tool for the antitumor immunotherapy. Previous research has shown that fusion hybrids of human DCs and autologous tumor cells can induce cytotoxic T lymphocyte (CTL) responses against autologous tumor cells in animal models and human clinical trials. However, a major restriction factor for the clinical use is the difficulty for preparation of sufficient amount of autologous tumor cells especially for the patients with metastasis cancer whose primary tumor lesion is not clear or has been resected. In this study, allogeneic breast cancer cell line MCF-7 cells were electrofused to autologous DCs from patient with breast cancer as a strategy to deliver shared breast cancer antigens to DCs. Fusion cells generated by autologous DCs and allogeneic MCF-7 were able to induce autologous T lymphocytes proliferation, high levels of IFN-gamma production and CTL responses. CTLs induced by DCs/allogeneic MCF-7 fusion cells were able to kill autologous breast cancer cells in an antigen specific and HLA restriction manner. Our study may provide the experiment basis for the use of allogeneic breast cancer cell line in the DC/tumor cell fusion cell vaccination strategy.
机译:树突状细胞(DC)/肿瘤细胞融合疫苗已被证明是抗肿瘤免疫疗法的有前途的工具。先前的研究表明,在动物模型和人类临床试验中,人DC和自体肿瘤细胞的融合杂交体可诱导针对自体肿瘤细胞的细胞毒性T淋巴细胞(CTL)反应。然而,临床使用的主要限制因素是难以制备足够量的自体肿瘤细胞,特别是对于原发性肿瘤病灶不清楚或已切除的转移癌患者。在这项研究中,将同种异体乳腺癌细胞系MCF-7细胞与乳腺癌患者的自体DC电融合,作为将共享的乳腺癌抗原递送至DC的策略。由自体DC和同种异体MCF-7产生的融合细胞能够诱导自体T淋巴细胞增殖,高水平的IFN-γ产生和CTL反应。 DC /异源MCF-7融合细胞诱导的CTL能够以抗原特异性和HLA限制方式杀死自体乳腺癌细胞。我们的研究可为在DC /肿瘤细胞融合细胞接种策略中使用同种异体乳腺癌细胞系提供实验依据。

著录项

  • 来源
    《Breast Cancer Research and Treatment》 |2007年第3期|277-286|共10页
  • 作者单位

    Center of Orthopaedic Surgery Orthopaedics Oncology Institute of Chinese PLA Tangdu Hospital Fourth Military Medical University Xi’an 710038 Shaanxi Province China;

    Center of Orthopaedic Surgery Orthopaedics Oncology Institute of Chinese PLA Tangdu Hospital Fourth Military Medical University Xi’an 710038 Shaanxi Province China;

    Center of Orthopaedic Surgery Orthopaedics Oncology Institute of Chinese PLA Tangdu Hospital Fourth Military Medical University Xi’an 710038 Shaanxi Province China;

    Center of Orthopaedic Surgery Orthopaedics Oncology Institute of Chinese PLA Tangdu Hospital Fourth Military Medical University Xi’an 710038 Shaanxi Province China;

    Center of Orthopaedic Surgery Orthopaedics Oncology Institute of Chinese PLA Tangdu Hospital Fourth Military Medical University Xi’an 710038 Shaanxi Province China;

    State Key Laboratory of Cancer Biology Department of Pathology Xi Jing Hospital Fourth Military Medical University Xi’an 710032 Shaanxi Province China;

    State Key Laboratory of Cancer Biology Department of Pathology Xi Jing Hospital Fourth Military Medical University Xi’an 710032 Shaanxi Province China;

    State Key Laboratory of Cancer Biology Department of Pathology Xi Jing Hospital Fourth Military Medical University Xi’an 710032 Shaanxi Province China;

    Center of Orthopaedic Surgery Orthopaedics Oncology Institute of Chinese PLA Tangdu Hospital Fourth Military Medical University Xi’an 710038 Shaanxi Province China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Allogeneic; CTL; Dendritic cells; Electrofusion; MCF-7;

    机译:同种异体;CTL;树突状细胞;电融合;MCF-7;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号